octreotide acetate / Generic mfg., Novartis 
Welcome,         Profile    Billing    Logout  

13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
octreotide acetate / Generic mfg.
2014-003856-30: Trial for patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR.

Ongoing
4
50
Europe
SANDOSTATIN LAR, Injection, Sandostatine Long Acting Repeatable (LAR) 10, 20, 30 mg
Cliniques Universitaires Saint Luc, Cliniques Universitaires Saint Luc, Novartis pharma SA/NV
The primary objective is to observe the change from baseline in the incidence of diarrhea and flushing in correlation to the serum octreotide level, independently of the dose variations of octreotide LAR., To observe the change from baseline in the incidence of diarrhea and flushing in relation to the serum octreotide level (level in the blood) independently of the dose variations of octreotide LAR., Diseases [C] - Cancer [C04]
 
 
CTR20221314: To compare the safety and efficacy of lutetium [177Lu] oxyoctreotide injection versus long-acting octreotide in patients with inoperable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neu

Ongoing
3
213
China
octreotide acetate solution for injection - Generic mfg.
Beijing Xiantong International Pharmaceutical Technology Co., Ltd
Unresectable or metastatic, progressive, well-differentiated (G1 and G2) and somatostatin receptor-positive adult patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
 
 
2022-000507-12: A randomized, controlled, open-label study of RYZ101 compared with standard of care therapy in subjects with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following 177Lu SSA therapy Ensayo aleatorizado, controlado y abierto de RYZ101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados SSTR+, avanzados e inoperables, que hayan progresado tras tratamiento con 177Lu SSA.

Not yet recruiting
3
288
Europe
RYZ101, Sunitinib, RYZ101, Sunitinib, L01XE04, Solution for injection, Tablet, Capsule, hard, Powder and solvent for suspension for injection, Solution for injection in pre-filled syringe, Everolimus Zentiva 5mg Tabletten, Szunitinib Mylan 12,5 mg, Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection, SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe, Szunitinib Sandoz 12,5 mg
RayzeBio, Inc., RayzeBio, Inc.
gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, Diseases [C] - Cancer [C04]
 
 
NETTER-2, NCT03972488 / 2019-001562-15: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Active, not recruiting
3
226
Europe, Canada, US, RoW
Lutathera, long-acting octreotide, high dose long-acting octreotide, Optional post-progression re-treatment with Lutathera, Optional post-progression cross-over to Lutathera, Optional post-progression re-treatment with Lutathera after cross-over
Advanced Accelerator Applications
Gastro-enteropancreatic Neuroendocrine Tumor
07/23
10/27
SORENTO, NCT05050942 / 2021-000849-40: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Active, not recruiting
3
332
Europe, Canada, US, RoW
CAM2029, Octreotide LAR, Lanreotide ATG
Camurus AB
Gastro-enteropancreatic Neuroendocrine Tumor
12/24
12/26
NCT05459844: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Recruiting
3
196
RoW
Lutetium[177Lu] Oxodotreotide Injection, 177Lu-DOTA0-Tyr3-Octreotate, Octreotide LAR, SANDOSTATIN LAR, Octreotide
Sinotau Pharmaceutical Group
Neuroendocrine Tumors
12/24
12/28
ACTION-1, NCT05477576: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Active, not recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus 10 mg, Sunitinib 37.5 MG, Octreotide LAR 60 MG Injection, Lanreotide 120Mg Sa Susp Inj Syringe
RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
07/25
07/28
NCT05884255: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Recruiting
3
220
RoW
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide.
Jiangsu HengRui Medicine Co., Ltd.
Advanced Gastroenteropancreatic Neuroendocrine Tumor
12/26
10/30
NCT01744249 / 2011-001550-29: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Active, not recruiting
2/3
255
Europe
Axitinib, Sandostatin LAR, Placebo
Grupo Espanol de Tumores Neuroendocrinos, Pfizer
Neuroendocrine Tumors, Advanced Cancer
08/21
10/21
2017-001613-83: NA NA

Not yet recruiting
2
34
Europe
SANDOSTATINA, OCTEOTRIDE, Powder and solvent for suspension for injection, SANDOSTATINA - LAR 30 MG/2.5 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE FLACONE POLVERE + SIRINGA PRERIEMPITA 2.5 ML + 2 AGHI
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, Novartis
patient with neuroendocrine tumors pazienti con tumore neuroendocrino, patient with neuroendocrine tumors pazienti con tumore neuroendocrino, Diseases [C] - Cancer [C04]
 
 
2019-001200-38: Is it possible to improve the nutritional recovery with a medicine called Sandostatin after surgery for esophageal or gastric cancer?

Not yet recruiting
2
172
Europe
Powder and solvent for suspension for injection, Sandostatin LAR 10mg
Karolinska Universitetssjukhuset, Karolinska Universitetssjukhuset, FoU-enheten PO övre buk B75
Undesired weight loss after operation for esophageal or gastric cancer, Undesired weight loss after operation for esophageal or gastric cancer, Body processes [G] - Metabolic Phenomena [G03]
 
 
LUMEN-1, NCT06326190: 177Lu-DOTATATE for Recurrent Meningioma

Not yet recruiting
2
135
NA
Local standard of Care, Hydroxycarbamide, Bevacizumab, Sunitinib, Octreotide (Sandostatin LAR), Everolimus, No active treatment (observation with regular follow-up and best supportive care), 177Lu-DOTATATE, ¹⁷⁷Lu-DOTA0-TATE, Lutathera®, Lu oxodotreotide
European Organisation for Research and Treatment of Cancer - EORTC, Novartis
Recurrent Meningioma
04/27
12/28
OXTEND-01, NCT05364944: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Active, not recruiting
1
30
Europe, RoW
Debio 4126, Sandostatin LAR, Octreotide acetate, Somatuline ATG, Lanreotide acetate
Debiopharm International SA
Acromegaly, GEP-NET
11/24
12/24

Download Options